DNAY - Codex DNA slide continues as shares down ~70% over last month
Shares of Codex DNA (NASDAQ:DNAY) closed down another ~11% today as the synthetic biology company's Q4 2021 results continue to weigh on the stock. Codex DNA (DNAY) released those results after the market close on March 23. Since then through closing Monday, shares are down 55% While maintaining an overweight rating, KeyBanc on Monday cut its price target to $8 from $30 (~94% upside based on Monday's close). The firm cited a collaboration and licensing agreement Codex DNA (DNAY) signed with Pfizer (PFE) in January regarding mRNA vaccines and therapies that could help boost revenue.
For further details see:
Codex DNA slide continues as shares down ~70% over last month